scholarly journals The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy

2020 ◽  
Vol 8 (5) ◽  
pp. 197
Author(s):  
Victoria Serhiyenko ◽  
Marta Hotsko ◽  
Alexandr Serhiyenko ◽  
Oksana Snitynska ◽  
Ludmila Serhiyenko ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipoic Acid ◽  
Cardiac Autonomic Neuropathy ◽  
Alpha Lipoic Acid ◽  
Inflammatory Parameters ◽  
The Impact

scholarly journals Effect of alpha-lipoic acid on arterial stiffness parameters in type 2 diabetes mellitus patients with cardiac autonomic neuropathy

2021 ◽  
Vol 55 (4) ◽  
pp. 224-233
Author(s):  
Victoria A. Serhiyenko ◽  
Ludmila M. Serhiyenko ◽  
Volodymyr B. Sehin ◽  
Alexandr A. Serhiyenko
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Arterial Stiffness ◽  
Lipoic Acid ◽  
Augmentation Index ◽  
Cardiac Autonomic Neuropathy ◽  
Alpha Lipoic Acid ◽  
Hypoglycemic Therapy

Abstract Objective. Significantly underdiagnosed, diabetes-associated cardiac autonomic neuropathy (CAN) causes a wide range of cardiac disorders that may cause life-threatening outcomes. This study investigated the effects of alpha-lipoic acid (ALA) on arterial stiffness and insulin resistance (IR) parameters in type 2 diabetes mellitus (T2D) patients and definite CAN. Methods. A total of 36 patients with T2D and a definite stage of CAN were recruited. This investigation was carried out on two separate arms: traditional hypoglycemic therapy (n=18, control) and ALA (n=18) 600 mg in film-coated tablets/q.d. in addition to traditional hypoglycemic therapy. The duration of the study was three months. Results. In subjects with T2D and definite stage of СAN, treatment with ALA resulted in a significant decrease of glucose, immunoreactive insulin concentration, and Homeostasis Model Assessment (HOMA)-IR (HOMA-IR) parameters; pulse wave velocity (PWV), aorta augmentation index (AIxao) during the active period of the day and decrease of PWV, AIxao, and brachial augmentation index during the passive period of the day compared with the results, obtained in the control group. Therefore, the administration of ALA to patients with T2D for three months promotes the improvement of glucose metabolism and arterial stiffness parameters. Conclusions. In patients with T2D and definite stage of СAN treatment with ALA improved HOMA-IR and arterial stiffness parameters. These findings can be of clinical significance for the complex treatment of diabetes-associated CAN.

scholarly journals Alpha-lipoic Acid: Effects on the Beat-to-Beat Vectorcardiographic Parameters in Type 2 Diabetes Mellitus Patients with Cardiac Autonomic Neuropathy

2021 ◽  
Vol 2 (2) ◽  
pp. 16
Author(s):  
Victoria Serhiyenko ◽  
Krystina Kozlovska ◽  
Alexandr Serhiyenko
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Autonomic Neuropathy ◽  
Lipoic Acid ◽  
Qt Dispersion ◽  
Cardiac Autonomic Neuropathy ◽  
Control Group ◽  
Alpha Lipoic Acid

Objective: Relevance of cardiac autonomic neuropathy has not been fully recognized and there is no standardized treatment protocol.Aim: To evaluate the effects of alpha-lipoic acid on the beat-to-beat vectorcardiographic parameters, namely spatial QRS-T angle, QT dispersion (QTd) and corrected QT interval (QTc) in type 2 diabetes mellitus persons with cardiac autonomic neuropathy. Research designs and methods: Our study involved 33 persons with definite stage of cardiac autonomic neuropathy and diabetes mellitus type 2, which were assigned to each of two groups: one took standard antihyperglycaemic treatmen (n=15, control group) and the other (n=18) in addition to standard therapy - 600 mg of alpha-lipoic acid daily for three months. The analysis of vectorcardiographic parameters was performed. Results: It was found out that alpha-lipoic acid contributed to decrease of the vectorcardiographic parameters, namely QRS-T angle, QTd and QTc. Conclusions: The positive influences of alpha-lipoic acid suggest the usefulness of its prescription to type 2 diabetes mellitus persons with definite stage of cardiac autonomic neuropathy. The efficacy of alpha-lipoic acid is the result of its direct effect on the parameters of vectorcardiography.

scholarly journals CARDIOVASCULAR AUTONOMIC NEUROPATHY: ALPHA-LIPOIC ACID, INSULIN RESISTANCE AND INFLAMMATORY PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

InterConf ◽  
2021 ◽  
pp. 314-321
Author(s):  
Victoria Serhiyenko ◽  
Marta Hotsko ◽  
Oksana Snytinska ◽  
Alexandr Serhiyenko
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Autonomic Neuropathy ◽  
Lipoic Acid ◽  
Tnf Alpha ◽  
Alpha Lipoic Acid ◽  
Hs Crp

This paper presents the results obtained during the study of possible alpha-lipoic acid (ALA) impact on the state of insulin resistance (IR), the content of some pro- and anti-inflammatory factors in patients with type 2 diabetes mellitus (T2DM) and cardiovascular autonomic neuropathy (CAN). Our study involved 33 persons with diagnosed T2DM and CAN, which were allocated to one of two groups. The control group (15 patients) received standard hypoglycemic treatment, whereas the intervention group (18 patients) received ALA 600 mg in film-coated tablets/q.d. in addition to standard therapy. Treatment period was 3 mos in duration. Levels of glycated hemoglobin A1c, glucose, immunoreactive insulin (IRI), leptin, interleukin (IL) IL-6 and IL-8, high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha) in the blood were measured. TNF-alpha/IL-10 ratio and Homeostasis model assessment IR (HOMA-IR) were calculated. The significant reduction in glucose, IRI, leptin concentration and HOMA-IR parameters; decrease in the hs-CRP, TNF-alpha, IL-6 and IL-8 levels, TNF-alpha/IL-10 ratio, with no changes in IL-10 content after 3 mos of treatment was found. The results of our study demonstrated the decrease in the pro-inflammatory link activity after treatment and allow us to consider ALA as one of the promising drug for complex treatment of CAN in patients with T2DM.

scholarly journals Effect of Transdermal Testosterone or Alpha-Lipoic Acid on Erectile Dysfunction and Quality of Life in Patients with Type 2 Diabetes Mellitus / Эффект применения трансдермального тестостерона или альфа-ли- поевой кислоты на эректильную дисфункцию и качество жизни пациентов со сахарным диабетом типа 2

Folia Medica ◽  
2013 ◽  
Vol 55 (1) ◽  
pp. 55-63 ◽  
Author(s):  
Mitko D. Mitkov ◽  
Ivanka Y. Aleksandrova ◽  
Maria M. Orbetzova
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Lipoic Acid ◽  
Hdl Cholesterol ◽  
Alpha Lipoic Acid

Abstract Erectile dysfunction (ED) is the inability to develop and/or maintain an erection that is sufficient for satisfactory sexual intercourse. The prevalence of erectile dysfunction in diabetic men is 28-75%, this percentage rising with patient’s age and duration of diabetes. The aim of the present study was to investigate erectile dysfunction and quality of life in patients with type 2 diabetes mellitus (T2DM) after treating them with transdermal testosterone or with alpha-lipoic acid. Materials and methods: The effect of a 12-week treatment with transdermal testosterone or alpha-lipoic acid on the erectile function and quality of life of 45 men with ED and T2DM was studied in a randomized, prospective, open clinical, comparative study. The parameters we measured in the patients were body weight and body mass index (BMI); the albumin, lipids, HbA1C, testosterone (T), sex hormone-binding globulin (SHBG), follicle stimulating hormone (FSH), luteinizing hormone (LH) and microalbuminuria levels; the International Index of Erectile Function (IIEF) and Health related quality of life (SF-36) questionnaires were completed to evaluate ED and quality of life before and after 12 weeks of treatment with alpha-lipoic acid (600 mg, parenterally, for 7 days, followed by 600 mg received per os) or with transdermal testosterone in a dose of 50 mg daily. Results: Testosterone treatment decreased BMI significantly (p < 0.01), increased testosterone concentrations (p < 0.01) and raised the SHBG levels (p < 0.05), improved the glycemic control and lipid profile (total cholesterol, p < 0.05; HDL cholesterol, p < 0.05; triglycerides, p < 0.05). The patients treated with alpha-lipoic acid had their BMI (p < 0.01), HbA1C (p < 0.01), total cholesterol (p < 0.01), HDL-cholesterol (p < 0.01) and triglycerides (p < 0.01) significantly reduced. The indicators for ED in both groups were also statistically significantly improved. There was improvement for all patients’ self-assessment score for “physical functioning” (p = 0.001), for “role limitations due to physical health” (p < 0.001) and for “general health perception” (p = 0.021). Conclusions: Transdermal testosterone and alpha-lipoic acid have a tangible beneficial effect on erectile dysfunction and on metabolic disorders in T2DM patients and can be used to treat such patients.

Sign in / Sign up

Export Citation Format

Share Document